Soligenix (NASDAQ: SNGX) is one of 93 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Soligenix to related companies based on the strength of its analyst recommendations, earnings, profitability, dividends, valuation, risk and institutional ownership.

Profitability

This table compares Soligenix and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Soligenix -86.15% -129.88% -74.33%
Soligenix Competitors -917.30% -187.05% -24.43%

Analyst Ratings

This is a summary of recent recommendations and price targets for Soligenix and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soligenix 0 0 2 0 3.00
Soligenix Competitors 163 542 1199 16 2.56

Soligenix currently has a consensus target price of $8.00, suggesting a potential upside of 255.56%. As a group, “Biotechnology” companies have a potential upside of 55.12%. Given Soligenix’s stronger consensus rating and higher probable upside, equities analysts plainly believe Soligenix is more favorable than its peers.

Risk and Volatility

Soligenix has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500. Comparatively, Soligenix’s peers have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.

Valuation & Earnings

This table compares Soligenix and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Soligenix $6.98 million -$6.76 million -1.65
Soligenix Competitors $223.74 million $57.84 million -0.65

Soligenix’s peers have higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

2.0% of Soligenix shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 5.0% of Soligenix shares are held by company insiders. Comparatively, 20.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Soligenix Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.